|
Bio-Synthesis launches RNATotalTM and other sample preparation kits with unmatched quality
RNA purification is of critical importance in the preparation of samples for use in several applications including cDNA library construction, gene expression assay, in vitro translation, microarrays, Northern blot analysis, nuclease protection assays, real-time quantitative PCR, reverse transcription PCR, RNA mapping etc. Low quality RNA may strongly compromise the experimental results of these applications which are often labor-intensive, time-consuming, and highly expensive.
However, RNA purification faces lot of challenges such as extracting high quality RNA from different types of cells and tissues, extracting RNA from scarce samples, especially in clinical settings. The most common method of RNA purification is phenol extraction. Even most of the kits currently available use a preliminary phenol extraction before further purification steps. However, the major drawback of phenol extraction is that, the RNA is contaminated with significant amounts of both DNA and polysaccharides as both can be present in the aqueous layer after phenol extraction. Both contaminants are precipitated along with RNA using ethanol or isopropanol and depending on the subsequent use of the RNA, they may affect further analyses.1 Moreover, phenol extraction is also cumbersome and hazardous to use.
Bio-Synthesis Inc. has launched the RNATotalTM Purification kit which can alleviate all challenges faced by researchers in obtaining quality RNA purification at unbelievably low price.
- RNATotal TM does not require phenol extraction step.
- It can extract total RNA including large messenger RNA (mRNA), small interfering (siRNA) RNA and microRNA from all samples.
- It can extract RNA from as little as a single cell and does not require a carrier to extract RNA.
- It can extract total RNA from all kinds of specimens including cultured cells, tissues, blood, serum, plasma, bacteria, yeast, fungi, plants and viruses.
This kit uses a proprietary resin-based technology. The kits are available in both columns as well as 96-well format.
Besides RNATotalTM Purification kit, Bio-Synthesis also has several other sample purification kits that are suited for different applications. There is also a composite kit for RNA, DNA and protein purification.
Bio-Synthesis - the world leader in custom services since 1984.
With the industry growing so rapidly, there are “young” companies sprouting all over the place. Many of these same companies are not successful and do not last very long. Bio-Synthesis has been the world leader in custom services since our inception in 1984. Over two decades of the highest quality of products, coupled with fast turnaround time and affordability has enabled BSI to stand in no one else’s shadow. Go with a company you know you can trust. Go with a company who cares about your research needs as much as you do. Whether its peptides, antibodies, DNA, RNA, or PNA, BSI will treat your needs like our own. Contact us now for your next quote, and see the difference a well-established company can make.
Synthesis of Novel Backbone Modified DNA
Bio-Synthesis inc., senior scientists Drs Jianhua Ye and Miguel Castro completed the synthesis of a new kind of modified DNA. Normally there is a phosphodiester backbone linking the nuecleotides in a DNA strand, however hese diester bonds are susceptible to degradation by DNA'ses, present in living cells. One way to extend the half life of DNA is by modifying the phosphodiester backbone. In this work four monomers were constructed, which upon chemical coupling produce a peptide like backbone which is unaffected by nucleases, thereby increasing the half life of these molecules and consequently extending its intended activity.
Bio-Synthesis announces Mini Gene synthesis services
The DNA Synthesis Division of Bio-Synthesis Inc is happy to announce another custom service: Mini Gene synthesis; with the capability to synthesize 100-200 bases long oligonucleotides we can put together small genes together; a small gene can be defined as one that encodes for 30-60 residuesin length. The ability to chemically synthesize proves very useful to the biomedical researcher that studies control of gene expression; a minigene can code for a peptide that can be an antagonist to a regulatory protein. We can deliver minigenes in about 5-7 days. For more information please call the DNA Synthesis Division.
Bio-Synthesis acquires sophisticated Multiple Peptide Synthesizer
Bio-Synthesis Inc is proud to announce the recent acquisition of a sophisticated Multiple Peptide Synthesizer, the Vantage from ACT, Louiville, Kentucky. This instrument has four dispensor tips, which allows for parallel washings, decreasing cycling times for peptide assembly. The Vantage is also equipped with a heating device which allows use to conduct reactions at 80 degrees Celsius, which expedites coupling times. This unit will help us to prepare a large number of peptides( 96 at a time) for applications such us peptide microarrays and discovery scale peptides; where researcher needs small quantities(imilligram or less) but in large numbers.
Bio-Synthesis releases updated peptide synthesis description
Bio-Synthesis has released an updated description for peptide synthesis; this allows peptide researchers to get a view of the broad spectrum of our capabilities.
Peptides are complex molecules and each peptide sequence is unique with regard to its chemical and physical properties. Peptides are synthesized by the solid-phase method using Fmoc chemistry on an Omega 396 multiple peptide synthesizer from Advanced ChemTech. The Core also uses an Applied Biosystems Model 431A Synthesizer for longer peptides. Synthesis is carried out at 50 µmole, 100 µmole or 250 µmole scales. On an average, a synthesis scale of 100 µmoles will yield about 50-70 mg of a 10-residue peptide and 100-150 mg of a 20-residue peptide depending on the substitution rating of the resin. The peptide synthesis service provides a complete spectrum of services that include, synthesis, cleavage, HPLC purification, peptide modifications, cyclization and mass analysis for quality assurance. Before submitting your peptide sequences to the Core, it is advisable to consider the following:
* Every peptide sequence synthesized is a unique one. Some peptides sequences are difficult to synthesize although, we attempt to synthesize every peptide sequence.
* Peptides with multiple cysteines, methionine, arginine and tryptophan residues can often be difficult to synthesize.
* Avoid a proline residue at the C-terminal of the peptide.
* The peptide will be de-protected and cleaved from the resin with 82.5-90% trifluoroacetic acid, partially purified, and lyophilized. The lyophilized material will be provided as a "crude" preparation. Turnaround time is about ten days to three weeks depending on the length of the peptide and purity level. When requested, the peptide will be purified further (see below).
For further questions please feel free to contact our Peptide Synthesis Division at 1800-227-0627
Peptide-PNA bioconjugates
Our peptide Synthesis Division has successfully developed methods to synthesize bioconjugates such us PNA’s linked to peptides; the hybrid molecule can be up to 60 residues in length and can be half PNA and half peptide linked together or they can be alternating PNA residues with peptide residues. This type of bioconjugates can be used to deliver peptide sequences inside a living cell, by using peptide sequences at one end that have the ability to penetrate the cell membrane and carry along a PNA, that can be targeted to a regulatory DNA sequence, then upon binding to it, it can interfere with its expression( production of a protein).
We are happy to announce that Biosearch Technologies of Novato, California, have extended Bio-Synthesis Inc, of Lewisville, Texas their line of Fluorescent dyes and quenchers for use in biomedical research applications. End users who source Biosearch dyes for any purpose other than non-commercial R&D applications will still be required to contact the Biosearch Technologies Licensing Department to obtain a Commercial Use License. These dyes are chemically couple to synthetic oligonucleotides and provide an excellent means for non-radioactive detection of DNA targets. Bio-Synthesis Inc have been providing custom synthetic oligonucleotides to the biomedical research community worldwide since 1984.
Bio-Synthesis Inc. was contracted by Georgia Cosmetics, Houston ,Texas to produce a series of peptides derived from colostrum. Georgia Cosmetics have filed for patents encompassing said peptides. Colostrum is the early mother’s milk thought to be important in providing the newborn with the elements necessary to establish the immune system of the child. Dr Jersey Georgiadis a world renowned protein expert is the CEO of Georgia Cosmetics, is also marketing tablets containing related peptides and other proprietary formulation that also stimulates an adult’s immune system.
Bio-Synthesis Inc was glad to sponsor the 19th Federation of North Texas Area Scientific Conference; the main speaker Dr. MacDonald from the Biochemistry Department at UT Austin spoke on Regulation of Gene Expression at the Translational Level, this subject is novel and appealing as most gene expression control was thought to be at the transcriptional level. A Texas style BBQ followed the conference where faculty and students of both Texas Woman University and the U. of North Texas had the chance to mingle and exchange with the invited speakers. Bio-Synthesis Inc. has sponsored the Federation meetings since 1,994 and hopes to continue doing so for many years to come.
Bio-Synthesis participates in CCCB Biotechnology Board
Bio-Synthesis Inc CEO Miguel Castro attended and formed part of the Collin County College Biotechnology(CCCB) Advisory Board; the mission of the Board is to advise the College in ways to improve the curriculum and to establish cooperative programs where the CCCB students /graduates perform internships with local biotech companies, where they can learn valuable hands on experience and give the local companies a chance to observe the performance of the students for possible permanent hiring. A number of local universities faculty form part of the board; these universities include: Texas A&M UT Southwestern,UT Dallas, U. of North Texas Health Science Center and other members are senior officers of local biotech companies. The CCCB campus is located in Collin County; Bio-Synthesis Inc is located in the adjacent county of Denton.
Bio-Synthesis Inc. Announces Exclusive Collaboration in the Area of Immune Agonists and Antagonists
LEWISVILLE, TX- January 23, 2008 – Bio-Synthesis Inc., a closely held biotechnology company, is pleased to announce an exclusive scientific collaboration with Dr. Dante Marciani, a world renowned expert in immune agonists. Over the last 20 years, Dr. Marciani has pioneered work with proprietary immune stimulatory saponins and their semi-synthetic analogs that have immune enhancing activities. These small molecule constructs have the potential to stimulate Th1 immunity thus become an important element in preventive vaccines as well as active immunotherapy. These plant-derived glycosides and their analogs have the unique ability to stimulate antigen-specific CTL production that will seek and destroy cells carrying abnormal markers, such as viral, intracellular parasites or tumor markers. Previous work by Dr. Marciani has been effective in stimulating a protective preventive immune response in commercial products, against various pathogens, such as retroviruses. These molecules have the capacity to stimulate both humoral and cell-mediated immunity; its inclusion in vaccines may result in a safe and protective immune response against infection. The collaboration between Dr. Marciani and BioSynthesis is focused on proprietary novel glycosides that stimulate innate immunity while taking advantage of the synergistic effects between innate and adaptive immunity. In addition, the collaboration extends to proprietary compounds that down regulate Th1 immunity, an area of significance in the treatment of chronic inflammatory conditions.
Bio-Synthesis Awarded NIH Grant to Develop Synergistic Adjuvants that Stimulate both Innate and Adaptive Immunities
Lewisville, TX - Bio-Synthesis, Inc. announced today that the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), has awarded the company a 2-year, $590,000, Small Business and Innovation Research (SBIR) Phase 1 grant. The company will use the proceeds to further the development of its proprietary adjuvants or immune agonists that carry in a single molecule the various determinants needed to stimulate both innate and adaptive immunities, causing synergistic effects on T cell immunity. This synergism may stimulate an exceptional Th1 immune response with production of cytotoxic T lymphocytes (CTLs), which would be advantageous in preventive vaccines against infectious agents like HIV-1. Because of their structure, these compounds may reverse the immune tolerance associated with aging and other conditions like malnutrition; as part of the formulation of therapeutic vaccines, they could be useful in stimulating an immune response medically effective in the treatment of certain chronic infectious diseases, such as HIV-1 and hepatitis viruses B and C. Due to their ameliorative effects of tolerance, these novel agonists may have applications in therapeutic vaccines against cancer, a group of diseases closely associated with aging.
Although the HIV-1 antigens required for an effective vaccine have been identified, this virus unusually high virulence has precluded so far the development of an effective vaccine. Apparently, the result of the body’s failure to produce a timely and effective protective immunity during the brief time elapsed between the virus entry and establishment of infection, as well as the capacity of the virus to develop mechanisms to scape immune surveillance. Thus, it is evident that stimulation of a protective immunity would require novel methods to stimulate a multi-prong immune response that would include both T-cell and humoral immunities as well as the more primitive but effective arm of the immune system: the innate immunity. Furthermore, it is most likely that an effective HIV-1 vaccine should also stimulate a protective immune response at the main points of viral entry: the body’s mucosal surfaces. The proposed Bio-Synthesis immune agonists have in their structures all of the determinants needed to stimulate these different immune responses that are apparently required to mount an effective protection against HIV-1 infection.
Another important application of these immune agonists would be to improve the immune system response of the aging population, the fastest growing group worldwide, which is likely to show an increased tolerance. In the US, the elderly population over 65 years old is expected to increase from 13% in the year 2000 to about 20% by the year 2030, in effect, an increase from 35 million to about 70 million people over 65 years of age. Use of these compounds in preventive vaccines, as influenza virus vaccine, should improve their performance which can be as low as 40% in the 65+ years old population, compared to 80% or better in the young populations. A situation that may explain the fact that in the US around 90% of the annual deaths attributed to influenza, occurs in people over 65 years of age.
“We are very pleased with the decision of the grants review committee to recognize the potential merits of our technology, and with the financial support of research activities by such a prestigious institution as the NIAID,” said Dr. Dante Marciani, lead scientist. “We believe that our immune agonists would play an important role in the development of a HIV-1 vaccine as well as to be a platform for the development of a wide variety of vaccines.”
About Bio-Synthesis:
Bio-Synthesis Inc, a closely held 25 year old biotechnology company active in the areas of proteomics, epigenetics, synthetic biology, carbohydrate chemistry, synthetic peptides and others; it specializes in constructing bio-conjugates including but not limited to peptides, DNA, RNA, small drugs and other compounds. It has one of the largest peptide synthesis facilities in the USA and can handle small and large volume projects.
As an experienced CRO, it can provide different types of synthetic DNA, long peptides of over 150 residues, antibodies, ASR (Analyte Specific Reagents) for DNA and peptide/protein based diagnostics, and a number of other services/products for the life sciences.
Contact Details:
Biosynthesis Inc.
Ian Flynn
Office of Business Liaison,
612 East Main Street Lewisville, TX 75057
Toll Free: 1-800-227-0627 ext. 209
Phone: 972-420-8505 ext. 209
Fax: 972-420-0442
Email: collaborations@biosyn.com
March 2, 2010
|
